Zotarolimus

Chemical structure of Zotarolimus

Zotarolimus is a macrolide immunosuppressant drug that is primarily used in drug-eluting stents to prevent coronary artery restenosis. It is a derivative of sirolimus, also known as rapamycin, and functions by inhibiting the mammalian target of rapamycin (mTOR), a key regulatory kinase involved in cell proliferation.

Mechanism of Action

Zotarolimus works by binding to the intracellular protein FKBP12 (FK506-binding protein 12). This complex then inhibits the mTOR pathway, which is crucial for cell cycle progression. By blocking mTOR, zotarolimus effectively reduces the proliferation of smooth muscle cells in the arterial wall, thereby preventing restenosis.

Clinical Use

Zotarolimus is primarily used in drug-eluting stents (DES), which are implanted in patients with coronary artery disease to keep the arteries open. The drug is released slowly from the stent to prevent the growth of scar tissue and restenosis, which is the re-narrowing of the artery.

Pharmacokinetics

Zotarolimus is designed to be released locally from the stent over a period of time, allowing for targeted action at the site of the stent placement. This local delivery minimizes systemic exposure and reduces the risk of systemic side effects.

Side Effects

As with other mTOR inhibitors, potential side effects of zotarolimus include immunosuppression, which can increase the risk of infections. Other side effects may include delayed wound healing and thrombocytopenia.

Related Pages

• Sirolimus
• Drug-eluting stent
• Coronary artery disease
• Mammalian target of rapamycin